for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Celsion Corporation

CLSN.OQ

Latest Trade

3.00USD

Change

0.05(+1.69%)

Volume

295,120

Today's Range

2.92

 - 

3.22

52 Week Range

0.69

 - 

3.64

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.95
Open
3.15
Volume
295,120
3M AVG Volume
22.18
Today's High
3.22
Today's Low
2.92
52 Week High
3.64
52 Week Low
0.69
Shares Out (MIL)
29.26
Market Cap (MIL)
86.31
Forward P/E
-5.23
Dividend (Yield %)
--

Next Event

Celsion Corp Annual Shareholders Meeting

Latest Developments

More

Celsion Reports Q1 Loss Per Share Of $0.20

Celsion Reports That Sufficient Events Have Been Reached For Second Interim Analysis Of Phase III Optima Study Of Thermodox In Primary Liver Cancer

Celsion Corporation Reports Qtrly Loss Per Share of $0.25

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Celsion Corporation

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Industry

Biotechnology & Drugs

Contact Info

997 Lenox Dr Ste 100

LAWRENCE TOWNSHIP, NJ

08648-2317

United States

+1.609.8969100

http://celsion.com/

Executive Leadership

Jeffrey Wayne Church

Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer

Khursheed Anwer

Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy

Nicholas Borys

Senior Vice President and Chief Medical Officer

Michael H. Tardugno

Executive Chairman of the Board, President, Chief Executive Officer

Donald Braun

Independent Director

Key Stats

1.80 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-2.720

2018

-1.270

2019

-0.770

2020(E)

-0.573
Price To Earnings (TTM)
--
Price To Sales (TTM)
172.62
Price To Book (MRQ)
5.42
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
61.08
LT Debt To Equity (MRQ)
47.04
Return on Investment (TTM)
-55.04
Return on Equity (TTM)
-46.34

Latest News

Latest News

BRIEF-Celsion Reports Data Safety Monitoring Board Recommendation To Proceed To Phase Ii Of The Ovation 2 Study In Advanced Ovarian Cancer

* CELSION REPORTS DATA SAFETY MONITORING BOARD RECOMMENDATION TO PROCEED TO PHASE II OF THE OVATION 2 STUDY IN ADVANCED OVARIAN CANCER

BRIEF-Celsion Reports Q1 Loss Per Share Of $0.20

* REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Celsion Reports That Sufficient Events Have Been Reached For Second Interim Analysis Of Phase III Optima Study Of Thermodox In Primary Liver Cancer

* CELSION REPORTS THAT SUFFICIENT EVENTS HAVE BEEN REACHED FOR THE SECOND INTERIM ANALYSIS OF THE PHASE III OPTIMA STUDY OF THERMODOX® IN PRIMARY LIVER CANCER

BRIEF-Celsion’s GEN-1 Immunotherapy Receives Orphan Drug Designation From The European Medicines Agency

* CELSION’S GEN-1 IMMUNOTHERAPY RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY

BRIEF-Celsion Announces Highly Encouraging Initial Clinical Results From The Phase I Portion Of The Phase I/II Ovation 2 Study With Gen-1 In Patients With Advanced Ovarian Cancer

* CELSION ANNOUNCES HIGHLY ENCOURAGING INITIAL CLINICAL RESULTS FROM THE PHASE I PORTION OF THE PHASE I/II OVATION 2 STUDY WITH GEN-1 IN PATIENTS WITH ADVANCED OVARIAN CANCER Source text for Eikon: Further company coverage:

BRIEF-On March 5, Celsion Delivered Notice To Aspire Capital Fund, Terminating Common Stock Purchase Agreement Dated Oct 28, 2019 - SEC Filing

* CELSION - ON MARCH 5, CO DELIVERED NOTICE TO ASPIRE CAPITAL FUND, TERMINATING COMMON STOCK PURCHASE AGREEMENT DATED OCT 28, 2019 - SEC FILING Source: (http://bit.ly/2TPdbG7) Further company coverage:

BRIEF-Celsion CEO Issues Letter To Stockholders

* CELSION CORP - DO NOT EXPECT ANY INTERRUPTION IN OUR SUPPLY OF THERMODOX OR GEN-1 FROM MANUFACTURING PARTNERS IN CHINA

BRIEF-Celsion Corporation Prices $4.8 Million Registered Direct Offering

* CELSION CORPORATION PRICES $4.8 MILLION REGISTERED DIRECT OFFERING

BRIEF-Celsion Phase III Clinical Study Of Thermodox In Combination With Radiofrequency Ablation To Continue According To Protocol

* PHASE III CLINICAL STUDY OF THERMODOX IN COMBINATION WITH RADIOFREQUENCY ABLATION TO CONTINUE ACCORDING TO PROTOCOL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Celsion Corporation Provides Corporate Update And 2018 Outlook

* CELSION CORPORATION PROVIDES CORPORATE UPDATE AND 2018 OUTLOOK

BRIEF-Celsion Announces FDA Clearance Of The OVATION II Study For The Evaluation Of GEN-1 Immunotherapy

* CELSION ANNOUNCES FDA CLEARANCE OF THE OVATION II STUDY FOR THE EVALUATION OF GEN-1 IMMUNOTHERAPY TO TREAT NEWLY DIAGNOSED STAGE III/IV OVARIAN CANCER

BRIEF-Celsion reports Q3 loss of $0.70/shr

* Celsion Corporation reports third quarter 2017 financial results and provides business update

BRIEF-Celsion files immunotherapy clinical protocol for the evaluation of Gen-1

* Celsion files immunotherapy clinical protocol for the evaluation of Gen-1 to treat newly diagnosed ovarian cancer

BRIEF-CELSION ANNOUNCES PRICING OF COMMON STOCK OFFERING

* CELSION CORPORATION ANNOUNCES PRICING OF UNDERWRITTEN OFFERING OF COMMON STOCK AND WARRANTS TO PURCHASE COMMON STOCK

BRIEF-Celsion provides update on Thermodox in liver cancer study

* Celsion provides update on Thermodox® in the Phase III Optima study of primary liver cancer

BRIEF-Celsion Corp Q2 loss per share $0.79

* Celsion corporation reports second quarter 2017 financial results and provides business update

BRIEF-Celsion Corp says DMC completes mid-study review of phase III thermodox optima study

* Data monitoring committee completes mid-study review of Celsion's phase III thermodox optima study in primary liver cancer

BRIEF-Celsion Corporation to delist from Tel Aviv stock exchange

* Celsion Corporation to delist from Tel Aviv stock exchange Source text for Eikon: Further company coverage:

BRIEF-Celsion Corp announces data from ovation study

* Celsion corp - announces latest translational data from ovation study in newly diagnosed advanced ovarian cancer patients Source text for Eikon: Further company coverage:

BRIEF-Celsion Corp says Anson Funds Management LP reported 9.6 pct passive stake in Co as of July 6 - SEC filing

* Anson Funds Management LP reports 9.6 percent passive stake in Celsion Corp as of July 6 - SEC filing Source text: (http://bit.ly/2uBZEHu) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up